NewTimeSpace News: The Hong Kong listing application of Beijing XSKY Technology Co., Ltd., submitted on 27 January 2026, has lapsed upon the expiry of the six-month validity period. Huatai International acted as the original sole sponsor. According to CIC Consulting data, measured by 2024 installed capacity, the Company is China’s largest independent distributed AI storage solution provider with a 10.4% market share and ranks as the second-largest distributed AI storage solution provider in China.
NewTimeSpace News: The Hong Kong listing application of Guangxi Yuchai Marine and Genset Power Co., Ltd., submitted on 27 January 2026, has lapsed upon the expiry of the six-month validity period. According to Frost & Sullivan data, the Company ranks as China’s largest supplier of power generation engines by 2024 domestic sales revenue, and the second-largest supplier of medium and high-speed marine engines in China. It recorded revenue of approximately RMB5 billion and net profit of roughly RMB762 million in the first nine months of 2025.
NewTimeSpace News: The Hong Kong listing application of Ningbo Deye Technology Corporation, submitted on 27 January 2026, has lapsed upon the expiry of the six-month validity period. CICC, CITIC Securities and CMBC International acted as the original joint sponsors. According to Frost & Sullivan data, the Company ranks as the world’s largest supplier of residential energy storage inverters by 2024 sales revenue. Its products are sold to over 150 countries and regions across six continents. It recorded operating revenue of approximately RMB11.21 billion in 2024, with overseas revenue accounting for 70.9%.
NewTimeSpace News: The Hong Kong listing application of Wayon Energy Technology Co., Ltd., submitted on 27 January 2026, has lapsed upon the expiry of the six-month validity period. CICC acted as the original sole sponsor. The Company is a digital energy solution provider with solid footprint in China and expanding global presence, focusing on three core sectors: intelligent power distribution network, data centre and new energy storage. Its businesses have extended to Southeast Asia, the Americas, Europe, Australia and other regions.
NewTimeSpace News: The Hong Kong listing application of Hangzhou Ganzhicao Technology Co., Ltd., submitted on 27 January 2026, has lapsed upon the expiry of the six-month validity period. China Securities International and SWHY HK acted as the original joint sponsors. Measured by 2024 revenue, the Company ranks first in China’s comprehensive online TCM service market with a 4.9% market share, and leads the online TCM consultation service market with a 16.7% market share. The platform boasts approximately 130,000 registered physicians and roughly 8 million registered users.
NewTimeSpace News: Leadrive Technology (Shanghai) Co., Ltd. has obtained filing approval from the CSRC. The Company plans to issue no more than roughly 35.21 million H Shares for listing on HKEX. Meanwhile, approximately 167 million domestic shares held by 56 shareholders will be converted into H Shares under the full circulation arrangement.
NewTimeSpace News: Jiangsu Slender West Lake Culture and Tourism Co., Ltd. has obtained filing approval from the CSRC. It intends to issue no more than around 51.47 million H Shares for listing on HKEX, and the filing approval notice is valid for 12 months.
NewTimeSpace News: Zhejiang Taotao Vehicles Co., Ltd. has secured filing approval from the CSRC. It plans to issue no more than roughly 13.94 million H Shares for listing on HKEX, and the filing approval notice is valid for 12 months.
NewTimeSpace News: Shida Shinghwa needs to supplement explanations for its overseas listing filing including supporting grounds for identification of dual-high projects and overcapacity, impacts of share pledges, borrowings and guarantees on control, approval status of overseas fundraising projects, impacts and disclosure sufficiency of pending litigations and arbitrations, as well as identification documents and penalty papers for work safety incidents. Legal counsel shall conduct verification and issue corresponding legal opinions.
NewTimeSpace News: QL Biopharmaceutical needs to supplement explanations for its overseas listing filing covering the basis for identifying a single controlling person under the concerted action agreement, pricing fairness for new shareholders, aggregation of shareholdings for related shareholders, compliance of equity incentives, patent utilisation and foreign investment access compliance including stem cell-related review, compliance of outbound investment procedures, and title status of full-circulation shares. Legal counsel shall conduct comprehensive look-through verification and issue legal opinions on the aforesaid matters.
NewTimeSpace News: XREAL Ltd. has recently received supplementary material requirements from the China Securities Regulatory Commission regarding its filing for overseas securities offering and listing. The inquiries cover five major matters: compliance of VIE structure dismantling, pricing fairness for new shareholders, compliance of equity incentive schemes, litigations and customs investigations involving domestic operating entities, and consistency of offering volume.
NewTimeSpace News: Amos Food (Group) Co., Ltd. recently received supplementary material requirements from the China Securities Regulatory Commission (CSRC) in relation to its filing application for overseas securities offering and listing. The Company is required to engage legal counsel to conduct verification and issue clear legal opinions covering multiple matters, including pricing rationality of capital increases and equity transfers, existence of historical shareholding nominee arrangements, fairness of share subscriptions by new shareholders in the latest 12 months, whether business scopes involve sectors subject to foreign investment restrictions, foreign exchange and investment compliance of overseas subsidiaries, progress of approval and filing procedures for overseas fund-raising projects, as well as the title status of shares held by shareholders participating in the full circulation scheme.
NewTimeSpace News: Arrano International Holdings Limited submitted a listing application to HKEX GEM on 24 July, with Lince Securities Finance acting as the sole sponsor. The Company is a Hong Kong security services provider that has undertaken security operations for large-scale infrastructure projects including the Three-runway System, with the maximum initial contract value reaching HK$295.5 million during the track record period. The Company has forayed into robotic security solutions and set up a joint venture with Guangzhou Huilun to develop security robots.
NewTimeSpace News: SHEIN Global Holdings Limited passed the Hong Kong Stock Exchange listing hearing on 26 July. Goldman Sachs, Morgan Stanley and JPMorgan act as joint sponsors. As the world’s largest online fashion destination, the Company served around 273 million active customers across approximately 160 markets in 2025, posting net revenue of USD41.8 billion with more than 2 million apparel styles available. The Company pioneered the Large-scale Automated Small-batch Quick-response (LATR) operating model.
NewTimeSpace News: NASN Intelligent Tech (Zhejiang) Co., Ltd. passed the Hong Kong Stock Exchange listing hearing on 26 July, with Haitong International and BOCI International acting as joint sponsors. The Company develops intelligent driving motion control technology. It is China’s first enterprise to deploy electric brake booster solutions for the commercial operation of L4 autonomous vehicles. Based on 2025 sales volume, it ranks among China’s top three domestic-owned drive-by-wire brake suppliers and the second-largest independent third-party domestic supplier.
NewTimeSpace News: PrimeGenX Therapeutics Co., Ltd. submitted its second listing application to HKEX on 24 July, with CITIC Securities and Minsheng Capital serving as joint sponsors. Founded in 2016, it is a biotech firm focused on local delivery targeted therapies for immune inflammatory diseases. Its core asset PG-011 (Pumecitinib), a small-molecule JAK1/2 inhibitor, is being developed in two formulations: pumecitinib gel for mild-to-moderate atopic dermatitis and pumecitinib nasal spray for moderate-to-severe allergic rhinitis. The Company has 63 R&D personnel, accounting for 73.2% of all full-time employees.
